ERBB2 and breast carcinoma: Molecular docking simulations of the combined particles conjugated with trastuzumab against human epidermal growth factor receptor 2 (HER2) as a target for breast cancer therapy exhibited an increase in the effectiveness of therapy as seen from the increase in the resulting docking score.